Raymond Alexanian, MD, Oral History Interview, May 15, 2014

Raymond Alexanian, MD, Oral History Interview, May 15, 2014

Files

Download Full Interview Transcript (391 KB)

Download Navigation Materials (72 KB)

Description

Major Topics Covered:

  • Personal and educational background;
  • Evolution of research on erythropoietin;
  • Evolution of research and contributions to treatment of myeloma;
  • History of medical education;
  • History of myeloma treatment;
  • Committees at MD Anderson: Research Committee, Surveillance Committee, Transfusion Task Force, Faculty Classification Committee;
  • The research and cultural environment of MD Anderson under Dr. R. Lee Clark

Identifier

AlexanianR_01_20140515

Publication Date

5-15-2014

Publisher

The Making Cancer History® Voices Oral History Collection, The University of Texas MD Anderson Cancer Center

City

Houston, Texas

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Topics Covered

University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, University of Texas System. M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute at Houston, University of Texas M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute

Disciplines

History of Science, Technology, and Medicine | Oncology | Oral History

About the Interview

About the Interview Subject

Dr. Raymond Alexanian (b. 8 June 1932, Queens, New York) joined MD Anderson in 1964 as an Assistant Professor of Medicine and served as Section Chief of Myeloma for many years. He retired in 2013 and holds Emeritus status. Dr. Alexanian achieved a national reputation through his work on erythropoietin, then shifted his specialization to cancer and to myeloma. At MD Anderson he innovated combination therapies for the disease. In collaboration with Bart Barlogie, MD, PhD, he developed a treatment combining chemotherapy and stem cell transplantation. Most recently he has written on the difficulty of defining “cure” in myeloma. In 2001 he received the Waldenström Award for his work in myeloma research.

Conditions Governing Access

Open

Raymond Alexanian, MD, Oral History Interview, May 15, 2014

Share

COinS